Acumen Pharmaceuticals (ABOS) Non Operating Interest Expenses (2021 - 2026)

Acumen Pharmaceuticals has disclosed Non Operating Interest Expenses across 5 years of filings, most recently posting $1.1 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 4.59% year-over-year to $1.1 million; the TTM figure through Jun 2026 stood at $4.3 million (up 4.48% YoY), while the FY2025 annual figure was $4.2 million, up 3.83% from the prior year.
• Non Operating Interest Expenses came in at $1.1 million for Q2 2026 at Acumen Pharmaceuticals, up from $1.1 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $1.1 million in Q2 2026 to a low of $581000.0 in Q4 2023.
• Average Non Operating Interest Expenses over 4 years is $1.0 million, with a median of $1.0 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses surged 78.49% in 2024 and advanced 2.3% in 2025.
• Over 4 years, Non Operating Interest Expenses stood at $581000.0 in 2023, then surged by 78.49% to $1.0 million in 2024, then gained by 4.82% to $1.1 million in 2025, then increased by 0.64% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $1.1 million in Q2 2026, $1.1 million in Q1 2026, and $1.1 million in Q4 2025.